Skip to main content
. 2013 Aug 1;8(8):e70608. doi: 10.1371/journal.pone.0070608

Figure 7. Small molecule ErbB2 inhibitors increase sensitivity to BCR/ABL-directed TKI.

Figure 7

Z119 cells were treated with indicated doses canertinib or lapatinib and (A) imatinib, (B) nilotinib or (C) dasatinib for 72 hours. Cells were stained with PI and the subdiploid population was measured by flow cytometry. Bars indicate the mean and SEM of at least three independent experiments.